The state of California currently has 79 active clinical trials seeking participants for Healthy research studies. These trials are conducted in various cities, including Los Angeles, San Francisco, San Diego and Sacramento.
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese
Recruiting
A study in healthy male and female participants of non-childbearing and childbearing potential who have overweight or obesity
Gender:
ALL
Ages:
Between 18 years and 142 years
Trial Updated:
04/17/2025
Locations: Research Site, Glendale, California
Conditions: Healthy Participants
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
Recruiting
This is a 3-part study that includes a Part A, Part B, and Part C. Part A will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese. Part B and Part C will study the safety and tolerability of LY3537031 in healthy participants. Part C will contain only Japanese and Chinese healthy participants. Blood tests will be performed to check how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it. Body wei... Read More
Gender:
ALL
Ages:
Between 22 years and 65 years
Trial Updated:
04/17/2025
Locations: Collaborative Neuroscience Research, LLC, Los Alamitos, California
Conditions: Healthy, Obesity
A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001)
Recruiting
The goal of this study is to learn whether a new vaccine, V330, is safe and learn how well the body's immune system responds by making antibodies after receiving V330.
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
04/17/2025
Locations: California Clinical Trials Medical Group managed by PAREXEL ( Site 0002), Glendale, California
Conditions: Healthy
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
Recruiting
Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
04/17/2025
Locations: California Clinical Trials Medical Group managed by PAREXEL ( Site 0011), Glendale, California
Conditions: Healthy
A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants
Recruiting
The main purpose of this study is to assess how olomorasib gets into the blood stream and how long it takes the body to remove it when administered to participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of olomorasib will also be evaluated. The study may last up to 6 weeks for each participant including the screening period.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: Orange County Research Center, Lake Forest, California
Conditions: Hepatic Insufficiency, Healthy
Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease
Recruiting
This study consists of 2 parts, Part A and Part B. Part A is a single center, randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of NMRA-323511 among healthy elderly. Part B is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group cohort to evaluate the safety, tolerability, and efficacy of NMRA-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease. Part A consists... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
04/16/2025
Locations: Neumora Investigator Site, Costa Mesa, California +2 locations
Conditions: Alzheimer's Disease, Healthy Elderly
A Study of Oral YUQ-A1007 in Healthy Volunteers
Recruiting
YUQ-A1007 is a novel gut-enriched AhR agonist. The nonclinical pharmacology study indicated that YUQ-A1007 has the potential to treat IBD. YUQ-A1007 has not been evaluated in human clinical studies. This study is first-in-human (FIH) study of YUQ-A1007. The goal of this trial is to evaluate the safety, tolerability, and pharmacokinetics of oral YUQ-A1007.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/15/2025
Locations: Anaheim Clinical Trials, Anaheim, California
Conditions: Healthy
Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants
Recruiting
The main objective of the study is to assess the safety and tolerability of AMG 378 as single or multiple doses in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/15/2025
Locations: Orange County Research Center, Lake Forest, California
Conditions: Healthy Volunteers
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
Recruiting
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2025
Locations: Anaheim Clinical Trials, LLC, Anaheim, California
Conditions: Healthy Participants, Atopic Dermatitis
24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
Recruiting
The goal of this clinical trial is to learn if a new contact lens device can record patterns in eye pressure for 24 hours in adults with glaucoma and in healthy participants. The main questions it aims to answer are: * Is the contact lens device able to detect patterns in eye pressure that happens naturally between nighttime and daytime? * Are the contact lens recording patterns similar when repeated one week later? * What eye problems do participants have when wearing contact lens for up to 2... Read More
Gender:
ALL
Ages:
Between 22 years and 80 years
Trial Updated:
04/15/2025
Locations: Nvision Clinical Reseacrh, LLC, Fullerton, California +2 locations
Conditions: Glaucoma, GLAUCOMA 1, OPEN ANGLE, D (Disorder), Ocular Hypertension, Ocular Hypertension (OH), Ocular Hypertension Glaucoma, IOP, Intraocular Pressure, Glaucoma Open-Angle, Glaucoma and Ocular Hypertension, Glaucoma Patients and Healthy Controls, Normal Tension Glaucoma (NTG)
A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants
Recruiting
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of AZD8965 via single and multiple ascending doses in healthy participants (including Japanese and Chinese participants), and to assess the effect of food on the safety, tolerability, and PK of orally administered AZD8965.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/14/2025
Locations: Research Site, Glendale, California
Conditions: Healthy Participants
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B)
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with Hemophilia A or Hemophilia B, with or without inhibitors (Part B).
Gender:
MALE
Ages:
Between 18 years and 60 years
Trial Updated:
04/11/2025
Locations: California Clinical Trials Medical Group (CCTMG), Glendale, California
Conditions: Healthy Participants, Hemophilia A, Hemophilia B